phase readout
saveNCT07155668: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE_NOT_RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: Viridian Therapeutics, Inc.. Phase: PHASE3. Conditions: Thyroid Eye Disease
view source ↗
comments(0)
5-min edit window · permanent after that